These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28535521)

  • 41. Extrarenal effects of FGF23.
    Haffner D; Leifheit-Nestler M
    Pediatr Nephrol; 2017 May; 32(5):753-765. PubMed ID: 27704252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease.
    Zisman AL; Wolf M
    Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):335-42. PubMed ID: 20583336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGF23 and mineral metabolism, implications in CKD-MBD.
    Rodríguez M; López I; Muñoz J; Aguilera-Tejero E; Almaden Y
    Nefrologia; 2012 May; 32(3):275-8. PubMed ID: 22592418
    [No Abstract]   [Full Text] [Related]  

  • 44. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Research on kidney and mineral metabolism in Japan: past, present, and future.
    Mizobuchi M; Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):4-8. PubMed ID: 28005175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Updates on Lifestyle-Related Diseases and Bone Metabolism. CKD-related osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2014 Nov; 24(11):1605-13. PubMed ID: 25355144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone and heart health in chronic kidney disease: role of dentin matrix protein 1.
    Martin A
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):297-303. PubMed ID: 31107286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysregulated mineral metabolism in children with chronic kidney disease.
    Shroff R
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):233-40. PubMed ID: 21422924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.
    Donate-Correa J; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Cytokine Growth Factor Rev; 2012; 23(1-2):37-46. PubMed ID: 22360923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease.
    Harjes LM; Parker VJ; Dembek K; Young GS; Giovaninni LH; Kogika MM; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):784-790. PubMed ID: 28419560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino M; Galassi A; Apetrii M; Covic A
    J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New biomarkers of CKD-MBD].
    Pasquali M; Tartaglione L; Rotondi S
    G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGF23 and Nutritional Metabolism.
    Pool LR; Wolf M
    Annu Rev Nutr; 2017 Aug; 37():247-268. PubMed ID: 28715994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management.
    Lewis R
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathophysiology of the chronic kidney disease-mineral bone disorder.
    Hruska KA; Seifert M; Sugatani T
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):303-9. PubMed ID: 26050115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone health in chronic kidney disease-mineral and bone disease.
    Gal-Moscovici A; Sprague SM
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.